Snowball logo
logo
AAVX_logo

ABIVAX Société Anonyme

$139.00$0.00  (0%)
Estimate
EPS
-6.06
Beta
-0.248
Growth
Net income, YoY
-13.49%
FCF, YoY
23.9%
About the company
Ticker
AAVXF
ISIN
US00370M1036
Country
France
Sector (GICS)
Healthcare
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Frequently asked questions

What sector does ABIVAX Société Anonyme (AAVXF) operate in?

ABIVAX Société Anonyme belongs to the Healthcare sector and operates in the Biotechnology industry.

What is ABIVAX Société Anonyme (AAVXF) current stock price?

As of the latest data, ABIVAX Société Anonyme stock price is $139.00, with a previous close of $139.00.

What is ABIVAX Société Anonyme (AAVXF) current market capitalization?

ABIVAX Société Anonyme market cap is approximately 12.13 billion.

What is ABIVAX Société Anonyme (AAVXF) Earnings Per Share (EPS)?

The trailing EPS is -$6.06.

What is ABIVAX Société Anonyme (AAVXF) EBITDA?

ABIVAX Société Anonyme EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -139.81 million.

Does ABIVAX Société Anonyme (AAVXF) pay dividends?

No. ABIVAX Société Anonyme does not pay a dividend.

What is ABIVAX Société Anonyme (AAVXF) beta (volatility) score?

ABIVAX Société Anonyme has a beta of -0.248, indicating lower volatility than the overall market.